Bafna Pharma.

Market Cap: Micro Cap
Industry: Pharmaceuticals & Biotechnology
ISIN: INE878I01022
NSEID: BAFNAPH
BSEID: 532989

INR

163.45

-8.55 (-4.97%)

BSENSE

Dec 26

BSE+NSE Vol: 4.91 k

{
  "main_header": {
    "sid": 852453,
    "name": "Bafna Pharma.",
    "stock_name": "Bafna Pharma.",
    "full_name": "Bafna Pharmaceuticals Ltd",
    "name_url": "stocks-analysis/bafna-pharma",
    "exchange": 0,
    "exchangecode": "",
    "country_id": 34,
    "currency": "INR",
    "cmp": "163.45",
    "chg": -8.55,
    "chgp": "-4.97%",
    "dir": -1,
    "prev_price": "172.00",
    "mcapval": "402.00 Cr",
    "mcap": "Micro Cap",
    "scripcode": 532989,
    "symbol": "BAFNAPH",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 4,
    "indexname": "",
    "isin": "INE878I01022",
    "curr_date": "Dec 26",
    "curr_time": "",
    "bse_nse_vol": "4.91 k",
    "exc_status": "Active",
    "traded_date": "Dec 26, 2025",
    "traded_date_str": "2025 12 26",
    "score": "",
    "scoreText": "",
    "Live": 1,
    "market_time": 1,
    "is_blur": 1,
    "is_blur_class": "blur-registerF-score-header",
    "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/bafna-pharma-852453-0&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0
    }
  },
  "news": {
    "results": [
      {
        "title": "Bafna Pharmaceuticals Hits Upper Circuit Amid Strong Buying Pressure",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/bafna-pharmaceuticals-hits-upper-circuit-amid-strong-buying-momentum-3768086",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/12/BafnaPharmaceut_stocks_hitting_upper_circuit_3768086.png",
        "date": "2025-12-24 10:00:32",
        "description": "Bafna Pharmaceuticals Ltd witnessed robust buying interest on 24 Dec 2025, hitting its upper circuit limit with a 5.0% gain to close at ₹173.26. The stock outperformed its sector and broader market indices, reflecting heightened investor enthusiasm and a surge in demand that led to a regulatory trading freeze."
      },
      {
        "title": "Bafna Pharmaceuticals Sees Shift in Market Assessment Amid Technical and Financial Developments",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/bafna-pharmaceuticals-upgraded-to-hold-by-marketsmojo-on-technical-and-financial-improvements-3767861",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/12/BafnaPharmaceut_mojoScore_3767861.png",
        "date": "2025-12-24 08:20:52",
        "description": "Bafna Pharmaceuticals has experienced a notable revision in its market evaluation, reflecting changes across technical indicators, financial trends, valuation metrics, and overall quality considerations. This shift highlights evolving investor perspectives on the pharmaceutical company’s performance and outlook within the Pharmaceuticals & Biotechnology sector."
      },
      {
        "title": "Bafna Pharmaceuticals Hits Upper Circuit Amid Strong Buying Pressure",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/bafna-pharmaceuticals-hits-upper-circuit-amid-strong-buying-momentum-3766889",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/12/BafnaPharmaceut_stocks_hitting_upper_circuit_3766889.png",
        "date": "2025-12-23 10:00:25",
        "description": "Bafna Pharmaceuticals Ltd witnessed robust buying interest on 23 Dec 2025, hitting its upper circuit limit with a maximum daily gain of 4.99%. The stock outperformed its sector and broader market indices, reflecting heightened investor enthusiasm and a surge in demand that led to a regulatory trading freeze."
      },
      {
        "title": "Why is Bafna Pharma. falling/rising?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/why-is-bafna-pharma-fallingrising-3766163",
        "imagepath": "",
        "date": "2025-12-23 01:52:39",
        "description": "    <div class=\"article-news-new\">\n        <div class=\"article-container\">\n\n<div class=\"article-content\">\n\n<p><strong>Intraday Price Movement and Trading Dynamics</strong></p>\n<p>On the trading day, Bafna Pharmaceuticals opened with a gap down of 4.74%, hitting an intraday low of ₹142.55. However, the stock rebounded strongly to touch an intraday high of ₹157.10, marking a significant recovery and closing near this peak. The wide trading range of ₹14.55 indicates heightened volatility, yet the stock’s ability to recover from the initial dip demonstrates resilience and buying interest among investors.</p>\n<p>Despite the weighted average price suggesting that more volume was traded closer to the day’s low, the stock managed to outperform its sector by 4.33%, signalling relative strength in comparison to its peers. This outperformance is particularly noteworthy given the broader market context and sector trend..."
      },
      {
        "title": "Bafna Pharmaceuticals Hits Upper Circuit Amid Strong Buying Pressure",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/bafna-pharmaceuticals-hits-upper-circuit-amid-strong-buying-pressure-3765479",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/12/BafnaPharmaceut_stocks_hitting_upper_circuit_3765479.png",
        "date": "2025-12-22 10:00:28",
        "description": "Bafna Pharmaceuticals Ltd witnessed robust buying interest on 22 Dec 2025, hitting its upper circuit limit with a maximum daily gain of 3.55%, closing at ₹155.00. The stock’s surge was accompanied by a regulatory freeze on further trading, reflecting intense demand and limited supply in the market."
      },
      {
        "title": "Bafna Pharma. Sees Revision in Market Evaluation Amid Mixed Financial Signals",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/bafna-pharma-downgraded-to-sell-by-marketsmojo-amid-valuation-concerns-3749783",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/12/BafnaPharma_mojoScore_3749783.png",
        "date": "2025-12-06 10:10:33",
        "description": "Bafna Pharma., a microcap player in the Pharmaceuticals & Biotechnology sector, has experienced a revision in its market evaluation reflecting a nuanced shift in its financial and technical outlook. This adjustment follows a period marked by strong stock returns but tempered by concerns over valuation and fundamental quality metrics."
      },
      {
        "title": "Bafna Pharmaceuticals Faces Intense Selling Pressure Amidst Consecutive Losses",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/bafna-pharmaceuticals-faces-severe-selling-pressure-amid-lower-circuit-lockdown-3749115",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/12/BafnaPharmaceut_only_sellers_3749115.png",
        "date": "2025-12-05 14:36:39",
        "description": "Bafna Pharmaceuticals has encountered significant selling pressure in recent trading sessions, with the stock registering a lower circuit and an absence of buyers in the queue. This distress selling signals a challenging phase for the company within the Pharmaceuticals & Biotechnology sector, as it underperforms both its sector and the broader market benchmarks."
      },
      {
        "title": "Bafna Pharmaceuticals Faces Intense Selling Pressure Amid Consecutive Losses",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/bafna-pharmaceuticals-faces-severe-selling-pressure-amid-lower-circuit-lockdown-3744340",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/12/BafnaPharmaceut_only_sellers_3744340.png",
        "date": "2025-12-03 13:35:44",
        "description": "Bafna Pharmaceuticals has encountered significant selling pressure in recent sessions, with the stock registering consecutive declines and a notable absence of buyers today. The pharmaceutical company’s shares have underperformed the broader market and sector indices, signalling distress selling and heightened market caution."
      },
      {
        "title": "Bafna Pharmaceuticals Faces Intense Selling Pressure Amid Lower Circuit",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/bafna-pharmaceuticals-faces-severe-selling-pressure-amid-lower-circuit-lockdown-3741826",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/12/BafnaPharmaceut_only_sellers_3741826.png",
        "date": "2025-12-02 13:20:46",
        "description": "Bafna Pharmaceuticals has encountered significant selling pressure today, with the stock hitting a lower circuit and an absence of buyers in the queue. This development signals distress selling and raises concerns about the stock's immediate market sentiment."
      }
    ],
    "total": 259,
    "sid": "852453",
    "stock_news_url": "https://www.marketsmojo.com/news/bafna-pharmaceuticals-852453"
  },
  "announcements": [
    {
      "caption": "Announcement under Regulation 30 (LODR)-Newspaper Publication",
      "datetime": "14-Nov-2025",
      "details": "We hereby enclose the Newspaper publication of the extract of the Unaudited Financial Results of the Company for the Quarter and Half Year ended September 30 2025 as published in Business Standard and Makkal Kural on November 13 2025.",
      "source": "BSE"
    },
    {
      "caption": "Unaudited Financial Results For The Quarter And Half Year Ended September 30 2025",
      "datetime": "11-Nov-2025",
      "details": "The Board of Directors of the Company in the Meeting held on November 11 2025 has inter-alia considered and approved the Unaudited Financial Results of the Company along with the Limited Review Report issued by the Statutory Auditors for the Quarter and Half Year ended September 30 2025.",
      "source": "BSE"
    },
    {
      "caption": "Board Meeting Outcome for Outcome For The Board Meeting Held On 11/11/2025",
      "datetime": "11-Nov-2025",
      "details": "The Board of Directors of the Compant in the meeting held on November 11 2025 has inter-alia considered and approved the Unaudited Financial Results of the Company along with the Limited Review Report issued by the Statutory Auditors of the Company for the Quarter and Half Year ended September 30 2025.",
      "source": "BSE"
    }
  ],
  "corporate_actions": [
    {
      "img": "board-meeting.svg",
      "title": "BOARD MEETING",
      "msg": "<span>No</span> Upcoming Board Meetings",
      "data": []
    },
    {
      "img": "dividend.svg",
      "title": "DIVIDEND",
      "msg": "",
      "data": [
        {
          "txt": "Bafna Pharmaceuticals Ltd has declared <strong>6%</strong> dividend, ex-date: 19 Sep 13",
          "dt": "2013-09-19",
          "middle_text": "Dividend Alert"
        }
      ]
    },
    {
      "img": "splits.svg",
      "title": "SPLITS",
      "msg": "No <strong>Splits</strong> history available",
      "data": []
    },
    {
      "img": "bonus.svg",
      "title": "BONUS",
      "msg": "No <strong>Bonus</strong> history available",
      "data": []
    },
    {
      "img": "rights-issues.svg",
      "title": "RIGHTS",
      "msg": "No <strong>Rights</strong> history available",
      "data": []
    }
  ]
}

News and Views

Bafna Pharmaceuticals Hits Upper Circuit Amid Strong Buying Pressure

2025-12-24 10:00:32

Bafna Pharmaceuticals Ltd witnessed robust buying interest on 24 Dec 2025, hitting its upper circuit limit with a 5.0% gain to close at ₹173.26. The stock outperformed its sector and broader market indices, reflecting heightened investor enthusiasm and a surge in demand that led to a regulatory trading freeze.

Bafna Pharmaceuticals Sees Shift in Market Assessment Amid Technical and Financial Developments

2025-12-24 08:20:52

Bafna Pharmaceuticals has experienced a notable revision in its market evaluation, reflecting changes across technical indicators, financial trends, valuation metrics, and overall quality considerations. This shift highlights evolving investor perspectives on the pharmaceutical company’s performance and outlook within the Pharmaceuticals & Biotechnology sector.

Bafna Pharmaceuticals Hits Upper Circuit Amid Strong Buying Pressure

2025-12-23 10:00:25

Bafna Pharmaceuticals Ltd witnessed robust buying interest on 23 Dec 2025, hitting its upper circuit limit with a maximum daily gain of 4.99%. The stock outperformed its sector and broader market indices, reflecting heightened investor enthusiasm and a surge in demand that led to a regulatory trading freeze.

Why is Bafna Pharma. falling/rising?

2025-12-23 01:52:39

Intraday Price Movement and Trading Dynamics

On the trading day, Bafna Pharmaceuticals opened with a gap down of 4.74%, hitting an intraday low of ₹142.55. However, the stock rebounded strongly to touch an intraday high of ₹157.10, marking a significant recovery and closing near this peak. The wide trading range of ₹14.55 indicates heightened volatility, yet the stock’s ability to recover from the initial dip demonstrates resilience and buying interest among investors.

Despite the weighted average price suggesting that more volume was traded closer to the day’s low, the stock managed to outperform its sector by 4.33%, signalling relative strength in comparison to its peers. This outperformance is particularly noteworthy given the broader market context and sector trend...

Bafna Pharmaceuticals Hits Upper Circuit Amid Strong Buying Pressure

2025-12-22 10:00:28

Bafna Pharmaceuticals Ltd witnessed robust buying interest on 22 Dec 2025, hitting its upper circuit limit with a maximum daily gain of 3.55%, closing at ₹155.00. The stock’s surge was accompanied by a regulatory freeze on further trading, reflecting intense demand and limited supply in the market.

Bafna Pharma. Sees Revision in Market Evaluation Amid Mixed Financial Signals

2025-12-06 10:10:33

Bafna Pharma., a microcap player in the Pharmaceuticals & Biotechnology sector, has experienced a revision in its market evaluation reflecting a nuanced shift in its financial and technical outlook. This adjustment follows a period marked by strong stock returns but tempered by concerns over valuation and fundamental quality metrics.

Bafna Pharmaceuticals Faces Intense Selling Pressure Amidst Consecutive Losses

2025-12-05 14:36:39

Bafna Pharmaceuticals has encountered significant selling pressure in recent trading sessions, with the stock registering a lower circuit and an absence of buyers in the queue. This distress selling signals a challenging phase for the company within the Pharmaceuticals & Biotechnology sector, as it underperforms both its sector and the broader market benchmarks.

Bafna Pharmaceuticals Faces Intense Selling Pressure Amid Consecutive Losses

2025-12-03 13:35:44

Bafna Pharmaceuticals has encountered significant selling pressure in recent sessions, with the stock registering consecutive declines and a notable absence of buyers today. The pharmaceutical company’s shares have underperformed the broader market and sector indices, signalling distress selling and heightened market caution.

Bafna Pharmaceuticals Faces Intense Selling Pressure Amid Lower Circuit

2025-12-02 13:20:46

Bafna Pharmaceuticals has encountered significant selling pressure today, with the stock hitting a lower circuit and an absence of buyers in the queue. This development signals distress selling and raises concerns about the stock's immediate market sentiment.

View All News

Announcement

Announcement under Regulation 30 (LODR)-Newspaper Publication

14-Nov-2025 | Source : BSE

We hereby enclose the Newspaper publication of the extract of the Unaudited Financial Results of the Company for the Quarter and Half Year ended September 30 2025 as published in Business Standard and Makkal Kural on November 13 2025.

Unaudited Financial Results For The Quarter And Half Year Ended September 30 2025

11-Nov-2025 | Source : BSE

The Board of Directors of the Company in the Meeting held on November 11 2025 has inter-alia considered and approved the Unaudited Financial Results of the Company along with the Limited Review Report issued by the Statutory Auditors for the Quarter and Half Year ended September 30 2025.

Board Meeting Outcome for Outcome For The Board Meeting Held On 11/11/2025

11-Nov-2025 | Source : BSE

The Board of Directors of the Compant in the meeting held on November 11 2025 has inter-alia considered and approved the Unaudited Financial Results of the Company along with the Limited Review Report issued by the Statutory Auditors of the Company for the Quarter and Half Year ended September 30 2025.